|
|
 |
|
Viewing report
|
|
|
|
Biotech 2010 Life Sciences: Adapting for Success
Burrill & Company, March 2010, Pages: 400
Charles Darwin told us that it is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change. Biotech 2010 - Life Sciences: Adapting for Success, the latest annual report on the industry, provides insight into biotech' s changing environment and how not to just survive but succeed.
Learn how to thrive
The publication provides thoughtful information and analysis on how companies need to adapt to major challenges to their business development in order to be successful in 2010 and beyond. These include: raising capital, impending healthcare reform, comparative effectiveness research, generics, biosimilars, reimbursement pressures and regulatory changes.
In addition Biotech 2010 presents:
- Comprehensive 2009 industry financials, private and public capital raised, M&A/Partnering activity of life sciences companies operating in the United States, Europe, Canada, and Asia.
- Analysis on key developments in healthcare, personalized medicine, biogreentech, emerging technologies, politics and policy and globalization...and much more.
A general outline of the reports chapters:
Chapter 1: Is Biotech' s Glass Half Full or Half Empty?
G. Steven Burrill, CEO of Burrill & Company, discusses how the industry still faces a number of challenges in 2010 and will need to be adaptable to face up to them and position themselves for success.
Chapter 2: An Industry Evolves
Top pharmaceutical companies are expected to lose more than $140 billion in annual revenue by 2016. That' s driving an aggressive effort by pharmaceutical companies to fill their pipelines with biotech products, reach into new markets, and find new ways to generate revenue.
Chapter 3: Emerging Technology Drives Personalized Medicine
A transformation of medicine is underway as new technologies are not only unlocking the genetics underlying disease, but ushering in a new era of personalized medicine.
Chapter 4: Combating the Rising Cost of Healthcare
Pharmaceutical, biotech, and medical device companies are facing a more hostile regulatory and legislative environment as governments seek to reign in healthcare costs. Companies will need to demonstrate their products are not only safe and effective, but provide true economic benefits over existing therapies.
Chapter 5: Advancing Toward a Bioeconomy
Biogreentech companies that survived the global recession are adapting to the challenging environment by broadening their platforms to include renewable chemicals and biopolymers, as well as opportunities in other markets.
Chapter 6: Acting Globally
As the process of globalization proceeds, the world is becoming flat, changing the dynamics of innovation and commercialization as well as the distribution of wealth and the incidence of disease. Any country that is prepared to nurture its venture capital and an entrepreneurial ecosystem is poised to benefit economically and not necessarily at the expense of another region.
Canada Latin America Europe Denmark Hungary Australia China India Japan South Korea Malaysia The Middle East
Chapter 7: Pharma Reinvents Itsel Through M&A and Partnering
Megadeals marked 2009 starting with Pfizer' s $68 billion acquisition of Wyeth, the merger of Merck and Schering Plough, and Roche' s acquisition of Genentech. Big pharmaceutical companies, at the edge of the patent cliff, were busy becoming biotechs either through acquisitions or partnerships.
Chapter 8: A Rough Ride on the Road to Recovery
The biotech industry closed its books on a year where the industry' s stock values dipped dramatically during a turbulent opening quarter, followed by slow, steady recovery. The V-shaped stock chart performance of biotech in 2009 mirrored what happened in the general capital markets. Despite the choppiness of the capital markets, three IPOs did get out the door, generating more than $1 billion, raising industry hopes that the IPO window was about to open.
Customers who bought this item also bought
Biotech 2011-Life Sciences: Looking Back to See Ahead
Biotech Life Sciences: A 20/20 Vision to 2020
Biotech Investment and Business Trends: Weathering the Economic Storm
Executing Change: Survival Strategies of Big Biotech
Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success
Biotech Investment and Business Trends: Surviving the Long Road to Market
Biotechnology - Global Outlook
Biotech Exit Strategies: Delivering Value to Investors in a Challenging Funding Market
Biotechnology in India - An Indian Market Report
The Funding Landscape for Small Biopharma Ventures, 2010-2015: Trends, Strategies and Priorities
|
|
|
|
